CTMX — CytomX Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1501989 ·
Last close
$3.10
Market Cap
$674.88M
52W High
$4.38
52W Low
$2.82
ADV30
4,753,100
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 10,258,000 | — | -19,672,000 | -18,248,000 | 359,358,000 | 28,828,000 | 39,414,000 |
| Dec 2025 | 663,000 | — | -27,932,000 | -26,510,000 | 151,566,000 | 12,667,000 | 52,558,000 |
| Sep 2025 | 5,963,000 | — | -15,768,000 | -14,229,000 | 158,254,000 | 34,185,000 | 50,865,000 |
| Jun 2025 | 18,658,000 | — | -1,286,000 | -154,000 | 175,057,000 | 49,041,000 | 55,147,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-75,587,000
Investing CF
$-59,744,000
Financing CF
$110,446,000
CapEx
$-427,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.25
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-711,949,000
Inventory
—
Receivables
$2,013,000
ST Investments
$124,385,000
EBIT TTM
$-22,365,000
Pretax Income TTM
$-17,131,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$35,542,000
EBITDA
$-60,615,000
Free Cash Flow
$-41,907,624
Enterprise Value
$331,028,064
Total Cash
$346,707,008
Total Debt
$2,856,000
Shares Out
217,702,919
Trailing EPS
$-0.52
Book Value
$1.47
ROE
-34.3%
ROA
-16.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 76,201,000 | -22,364,000 | -17,368,000 | 151,566,000 | 52,558,000 | — | -75,587,000 |
| Dec 2024 | 138,103,000 | 24,995,000 | 31,869,000 | 120,533,000 | 120,989,000 | — | -86,231,000 |
| Dec 2023 | 101,214,000 | -6,484,000 | -569,000 | 201,792,000 | 249,239,000 | — | -56,035,000 |
| Dec 2022 | 53,163,000 | -101,335,000 | -99,317,000 | 260,891,000 | 346,642,000 | — | -110,788,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.49
Max Pain — expiry 2026-08-21
max pain strike: $4.00 · spot: $3.10 · call oi: 2,605 · put oi: 7,000
Expected Move to 2026-08-21:
±$0.48
(15.65%) —
implied range
$2.61 –
$3.58
· ATM straddle on $3.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| STTK | Shattuck Labs, Inc. | $675.24M | $7.07 | — |
| NVCT | Nuvectis Pharma, Inc. | $678.43M | $21.52 | — |
| EVO | Evotec SE | $678.79M | $1.91 | — |
| RIGL | RIGEL PHARMACEUTICALS INC | $681.06M | $36.81 | — |
| CLYM | Climb Bio, Inc. | $681.43M | $11.90 | — |
News headlines (Yahoo Finance, 1h cache)
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-30 12:00 · Yahoo
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
2026-07-27 12:00 · Yahoo
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why
2026-07-08 16:00 · Yahoo
Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now?
2026-06-19 07:00 · Yahoo
How The Narrative Around CytomX Therapeutics (CTMX) Is Evolving With Recent Developments
2026-06-11 17:12 · Yahoo
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results
2026-06-05 18:22 · Yahoo
REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
2026-06-04 17:25 · Yahoo
Why Regeneron (REGN) Stock Is Trading Up Today
2026-06-04 00:31 · Yahoo
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
2026-06-03 12:00 · Yahoo
CytomX (CTMX) Q4 2025 Earnings Transcript
2026-06-02 17:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.